KIT A829P

CI-VAR-00000143Explore in graph →NP_000213.1:p.Ala829ProNM_000222.2:c.2485G>CClinVar 375933 CIViC 990 rs1057519713

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastrointestinal Stromal Tumor4
KIT A829P	Ponatinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID5862 Ponatinib possesses potent activity against most major clinically-relevant KIT mutants, and has demonstrated preliminary evidence of activity in patients with refractory GIST. These data strongly supp… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
KIT A829P	Ponatinib	Predictive	D	Does Not Support Resistance	4	accepted	EID7413 Ponatinib possesses potent activity against A829P KIT mutant cells in preclinical experiments. A preclinical study tested the effect of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with repre… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
375933	Pathogenic	criteria provided, single submitter	1	Gastrointestinal stromal tumor; Germ cell tumor of testis; Germinoma	germline/somatic	3	Aug 21, 2025	clinvar